1. Introduction {#sec1}
===============

Atherothrombosis is a systemic disease that often occurs at more than one vascular site and should be considered in practice as an integral disease \[[@B1]--[@B3]\]. Moreover, patients with affected arterial disease are more likely to develop higher event rates than patients with multiple risk factors only \[[@B3], [@B4]\]. Polyvascular disease (PolyVD) defined as presence of more than one affected vascular bed, that is, any combination of the following: coronary artery disease (CAD), peripheral arterial disease (PAD), and cerebrovascular disease (CVD) \[[@B5]--[@B9]\]. The frequency and impact of PolyVD in patients with acute coronary syndrome (ACS) in the Gulf region of the Middle East have not been studied yet. These countries have higher prevalence of the traditional risk factors in a unique fashion \[[@B1]\]. The aim of the current study is to evaluate the prevalence of PolyVD and its impact on the in-hospital major adverse events and 1-year mortality across ACS in a Middle Eastern population.

2. Methods {#sec2}
==========

2.1. Study Population {#sec2.1}
---------------------

Data were collected from a prospective, multicenter study of the 2nd Gulf Registry of Acute Coronary Events (Gulf RACE-2) between October 2008 and June 2009. We recruited 7,930 consecutive patients with ACS from 6 adjacent Middle Eastern Gulf countries (Bahrain, Kingdom of Saudi Arabia, Qatar, Oman, United Arab Emirates, and Yemen). Patients diagnosed with ACS, including unstable angina (UA) and non-ST- and ST-elevation myocardial infarction (NSTEMI and STEMI, resp.), were enrolled from 65 hospitals. On-site cardiac catheterization laboratory was available in 43% of the participating hospitals. All prospective patients with ACS were eligible for enrollment. The study received ethics approval from the institutional review boards in all participating hospitals. Full details of the methods have been previously published \[[@B10]\].

2.2. Definitions {#sec2.2}
----------------

*ACS:* diagnosis of the different types of ACS and definitions of data variables were based on the American College of Cardiology clinical data standards \[[@B10], [@B11]\]. Peripheral arterial disease (PAD): defined as presence of *any of the* following: intermittent claudication, critical limb ischemia (ulcer or gangrene), peripheral bypass surgery (surgical bypass for PAD indication), or peripheral percutaneous transluminal angioplasty. *Polyvascular disease* (PolyVD) was defined as presence of more than one affected vascular bed, that is, CAD, cerebrovascular disease (CVD), and asymptomatic or symptomatic peripheral arteries (PAD) \[[@B6]\]. A case report form (CRF) for each patient with suspected ACS was filled out upon hospital admission by assigned physicians and/or research assistants using standard definitions and was completed throughout the patient\'s hospital stay. All CRFs were verified by a cardiologist then sent online to the principal coordinating center, where the forms were further checked for mistakes before submission for final analysis.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Data are presented as proportions or mean ± standard deviation (SD) as appropriate. Baseline demographic characteristics, past medical history, clinical presentation, and clinical outcomes were compared between 2 groups (ACS with versus without PolyVD). Subanalysis was performed comparing the clinical outcomes among various combinations of vascular bed affection (ACS alone, ACS plus PAD, ACS plus CVD, and ACS plus PAD and CVD). Statistical analyses were conducted using the Student\'s *t*-test for continuous variables and Pearson chi-square (*χ* ^2^) test for categorical variables. Primary endpoints included recurrent ischemia, heart failure (HF), stroke, major bleedings, and mortality. All-cause mortality was assessed at 1-month and 12-month follow-up period. In order to assess the independent association of PolyVD with clinical outcomes, logistic regression analysis models were used and crude and adjusted odd ratios were calculated. We included significant baseline variables in the analysis such as age, sex, diabetes mellitus, hypertension, dyslipidemia, smoking, renal failure, prior coronary artery disease and prior coronary revascularization in addition to the type of ACS at presentation. Univariate and multivariate analysis for clinical outcomes were tested. Global Registry of ACS events (GRACE) risk scores for hospital mortality were used to stratify the risk status of patients at presentation as low, intermediate, or high \[[@B12]\]. All *P* values were the results of 2-tailed tests and values \<0.05 were considered significant. Data analysis was carried out using the Statistical Package for Social Sciences version 18 (SPSS Inc., USA).

3. Results {#sec3}
==========

3.1. Clinical and Biochemical Profiles {#sec3.1}
--------------------------------------

Out of the 7689 patients who were admitted with ACS, PolyVD was documented in 428 patients (5.6%) in terms of ACS plus PAD (110 patients), ACS plus CVD (284 patients), and ACS plus PAD and CVD (34 patients). [Table 1](#tab1){ref-type="table"} shows the baseline characteristics and risk factors of patients with PolyVD including ACS in comparison to ACS-alone patients. Patients with PolyVD were 6 years older (62 ± 11 versus 56 ± 12, *P* \< 0.0001) and were more likely to be female (31% versus 20%, *P* = 0.001). PolyVD patients were more likely to have risk factors such as diabetes mellitus (67% versus 38%, *P* = 0.001), hypertension (78% versus 45%, *P* = 0.001), dyslipidemia (55% versus 36%, *P* = 0.001), and renal failure (14% versus 3%, *P* = 0.001). They were less likely to be smokers (45% versus 54%, *P* = 0.001). On presentation with ACS, PolyVD patients had higher heart rate, and GRACE risk score and were more likely to present with a higher Killip class (*P* = 0.001 for all). NSTEACS was the most frequent diagnosis in PolyVD patients whereas STEMI was the predominant diagnosis in ACS-alone group.

3.2. In-Hospital Treatment Pattern {#sec3.2}
----------------------------------

[Table 2](#tab2){ref-type="table"} demonstrates the treatment pattern for patients with and without PolyVD. In regard to on-admission therapy, there were no differences between the two groups in the use of heparin and glycoprotein inhibitors. Apart from thrombolysis therapy use that was in favor of ACS-alone group, patients with PolyVD were more likely to be treated with oral antiplatelet, angiotensin-converting enzyme inhibitors, statin, and *β*-blockers. Coronary intervention was more frequently used in ACS-alone group in comparison to PolyVD patients. Aspirin, statin, and *β*-blockers were more frequently used during hospitalization and at discharge in ACS-alone patients.

3.3. Predictors for Polyvascular Disease {#sec3.3}
----------------------------------------

Multivariate logistic regression analysis showed that the important independent predictors for the presence of PolyVD in ACS patients were diabetes mellitus (adjusted OR 2.28; 95% CI 1.81--2.89), renal failure (adjusted OR 2.32; 95% CI 1.54--3.03) and hypertension (adjusted OR 2.66; 2.03--3.49), *P* = 0.001 for all ([Table 3](#tab3){ref-type="table"}).

3.4. Clinical Outcomes {#sec3.4}
----------------------

[Figure 1](#fig1){ref-type="fig"} demonstrates the clinical outcomes in different vascular disease combinations. [Table 2](#tab2){ref-type="table"} shows hospital outcomes in PolyVD versus ACS-alone group. All primary endpoints were significantly worse in PolyVD except for major bleedings. One- and 12-month all-cause mortality was 2-times greater in PolyVD group. Univariate analysis showed that PolyVD was predictor for reischemia, HF, stroke, and hospital, 1, and 12-month mortality (*P* = 0.001 for all). Similarly, multivariate logistic regression analysis denoted that PolyVD was an independent predictor for all outcomes except for major bleeding. PolyVD was strong predictor for in-hospital stroke (adjusted OR 5.40; 95% CI 2.17--13.29, *P* = 0.001  [Table 4](#tab4){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}).

3.5. Gender and Polyvascular Disease {#sec3.5}
------------------------------------

In comparison to their counterparts with ACS alone, men and women with PolyVD were older and had higher percent of commodities except for smoking. When compared to men, women with ACS alone had significant worse outcomes in terms of re-ischemia (18% versus 14%), in-hospital mortality (6.3% versus 3.7%), 1-month mortality (9.7% versus 6.8%), *P* = 0.001 for all. In all forms of PolyVD, there were no significant morbidity and mortality differences between men and women ([Table 5](#tab5){ref-type="table"}).

[Table 6](#tab6){ref-type="table"} shows risk factors and in-hospital mortality in patients with versus without polyvascular disease presenting with acute coronary syndrome in 3 major clinical studies.

4. Discussion {#sec4}
=============

The present study reports on the frequency, predictors and implication of PolyVD in patients presenting with ACS in the Gulf Region of the Middle East. Up to our knowledge, PolyVD in ACS patients was not reported in the Middle East before. There are several key findings in this study. *First*, PolyVD is a common disorder in that region in the setting of acute coronary events and represents a marker of high-risk population. The prevalence of PolyVD in the current study (5.6%) is over 2-fold lower versus GRACE study (15.6%), Alliance project (13%), and MASCARA study (16.6% [Table 6](#tab6){ref-type="table"}). Among the 4 studies, the high percent of young age, DM, and renal failure were observed in the current study. However, the difference in presentations and outcomes in the 4 studies may in part relate to diversity of biological and environmental factors between the different ethnicities. This observation needs further confirmatory studies. *Second*, PolyVD is associated with higher mortality rate even after adjusting for baseline variables. *Third*, at presentation, those patients were more likely to have atypical presentation, high resting heart rate, high Killip class, and high GRACE risk score. Moreover, NSTEACS was the most frequent diagnosis in PolyVD in comparison to ACS-alone group. Our findings are consistent with data from Western reports \[[@B5]--[@B9]\]. These studies showed that the management of PolyVD group was less aggressive in terms of less in-hospital coronary intervention and less evidence-based therapies during hospitalization and at discharge \[[@B6]--[@B8]\]. Several factors could explain the undertreatment trend in PolyVD group such as high percent of comorbidities with subsequent contraindication of some medications, physician and patient discretion, and possible socioeconomic factors. Understanding such reasons may reduce this therapy imbalance. *Fourth*, the current study shows that increasing the number of the affected vascular bed is associated with the worst clinical scenario ([Figure 1](#fig1){ref-type="fig"}). Apart from major bleedings, PolyVD is independent predictor for all in-hospital adverse outcomes. PolyVD increased risk of stroke 5-times even after adjustment for other covariates. PAD increased rate of HF and hospital mortality by 3-times whereas presence of CVD increased rate of in-hospital stroke 4-times. Data from [Table 5](#tab5){ref-type="table"} indicates that the highest mortality rate was observed in patients with PAD in our study, in patients with CVD in ALLIANCE project, and in patients with triple vascular bed affection in MASCARA and our study. Data from the Japanese REACH registry \[[@B13]\] denoted that the rates of 1-year stroke and myocardial infarction were higher for patients with CVD and PAD than for patients with CVD and CAD; however, that study was not carried out during the acute setting of coronary artery disease and did not report on the in-hospital rate of stroke. *Fifth*, the present study expands the previous reports and shows that diabetes mellitus, hypertension, and renal failures are independent predictors for the presence of PolyVD. This finding highlights the importance of primary and secondary prevention in this high-risk population. *Sixth*, male gender has better outcomes in ACS alone in comparison to female. These unfavorable outcomes associated with female gender were shown in our previous work as well \[[@B14]\]. Interestingly, presence of PolyVD is not associated with significant differences in the outcomes between men and women, this finding warrants further exploration.

5. Limitation {#sec5}
=============

The current study is an observational study; however, well-designed observational studies may provide valid results. Another limitation of the current retrospective analysis is that the diagnosis of PAD relied on the clinical history and not on the measurement of ankle-brachial index (ABI). This limitation could be explained in part by facts that clinical variables used are incompletely sensitive to identify PAD, approximately half of subjects with ABI \<0.90 are asymptomatic, and of those that are symptomatic, only a minority have classic intermittent claudication. The presence of PolyVD is underdiagnosed in our daily practice that may underestimate its true prevalence and impact on the outcome.

6. Conclusion {#sec6}
=============

Although PolyVD\'s patients are high-risk population in the setting of ACS, they received less aggressive therapy. Apart from major bleedings, PolyVD is an independent predictor for adverse hospital outcomes and short- and long-term mortality. Great efforts should be directed to primary and secondary prevention. Looking for the other affected vascular bed in ACS patients will add an important step in risk stratification and management.
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###### 

Risk factors and clinical and laboratory findings in patients with acute coronary syndrome with and without polyvascular disease.

                                  ACS alone (*n* = 7261)   Polyvascular disease (*n* = 428)   *P* value
  ------------------------------- ------------------------ ---------------------------------- -----------
  Age                             56 ± 12                  62 ± 12                            0.001
  Female                          20                       31                                 0.001
  Diabetes mellitus               38                       67                                 0.001
  Hypertension                    45.3                     78                                 0.001
  Dyslipidemia                    36                       55                                 0.001
  Smoking                         54                       45                                 0.001
  Renal failure                   3                        14                                 0.001
  Prior coronary artery disease   39                       64                                 0.001
  Prior revascularization         11                       25                                 0.001
  Khat chewing                    19                       20                                 0.92
                                                                                              
  *Clinical presentation*                                                                     
  Atypical presentation ACS       15                       28                                 0.001
  Heart rate                      84 ± 20                  90 ± 22                            0.001
  Systolic blood pressure         135 ± 29                 140 ± 35                           0.01
  Diastolic blood pressure        81 ± 17                  79 ± 20                            0.02
  Unstable angina                 24                       24                                 
  Non-STEMI                       29                       45                                 0.001
  STEMI                           47                       31                                 
  Killip class \> 1               21                       45                                 0.001
  Low GRACE risk score            41                       19                                 0.001
  High GRACE risk score           20                       43                                 
                                                                                              
  *Laboratory findings*                                                                       
  Fasting blood sugar (mmol/L)    7.3 ± 3                  8.1 ± 3                            0.001
  First hemoglobin (g/dL)         13.7 ± 2                 12.5 ± 2                           0.001
  Serum creatinine (umol/L)       100 ± 72                 130 ± 110                          0.001
  Hemoglobin A1c (%)              7.6 ± 2.4                8 ± 2.4                            0.15
  Total cholesterol (mmol/L)      4.9 ± 1.6                4.4 ± 1.6                          0.001
  Serum triglyceride (mmol/L)     1.8 ± 1.1                1.6 ± 0.8                          0.001
  Low-density lipoprotein         3.2 ± 1.3                2.8 ± 1.2                          0.001
  High-density lipoprotein        1.05 ± 0.5               0.99 ± 0.4                         0.01
  Peak troponin T                 1.4 ± 0.7                1.3 ± 0.6                          0.02
  LV ejection fraction \<50%      73                       85                                 0.001
  1-vessel CAD                    29                       48                                 0.001
  2-vessel CAD                    25                       18                                 0.12
  3-vessel CAD                    30                       17                                 0.004

All categorical and continuous variables are given in percent and mean ± SD, respectively.

###### 

Management and clinical outcomes in patients with acute coronary syndrome with and without polyvascular disease.

                               ACS alone (*n* = 7261)   Polyvascular disease (*n* = 428)   *P* value
  ---------------------------- ------------------------ ---------------------------------- -----------
  *On admission therapy %*                                                                 
  Aspirin                      38                       74                                 0.001
  Clopidogrel                  11                       23                                 0.001
  *β*-blockers                 28                       43.5                               0.001
  ACE inhibitors               24                       46                                 0.001
  Statins                      29                       58                                 0.001
  Thrombolysis\*               52                       20                                 0.001
  Unfractionated heparin       42                       40                                 0.46
  LMW heparin                  37                       41                                 0.12
  Glycoprotein inhibitors      7.7                      8                                  0.82
                                                                                           
  *During hospitalization %*                                                               
  Aspirin                      98.5                     96                                 0.001
  Clopidogrel                  76                       81                                 0.02
  *β* blockers                 75                       68                                 0.002
  ACE inhibitors               71                       69                                 0.31
  Statins                      95                       92.5                               0.03
  Coronary angiography         39                       31                                 0.002
  PCI                          22                       12.4                               0.001
                                                                                           
  *Discharge medications %*                                                                
  Aspirin                      96                       92                                 0.001
  Clopidogrel                  68                       70                                 0.32
  *β* blockers                 80                       74                                 0.01
  ACE inhibitors               72                       63.5                               0.001
  Statins                      92                       85                                 0.001
                                                                                           
  *Outcomes %*                                                                             
  Reischemia                   15                       23.4                               0.001
  Heart failure                11.6                     29.7                               0.001
  Stroke                       0.6                      2.3                                0.001
  Bleedings                    0.6                      0.9                                0.31
  Hospital death               4.2                      9.1                                0.001
  1-month death                7.4                      16.3                               0.001
  12-month death               11.2                     24.6                               0.001

\*ST-elevation MI, PCI: percutaneous coronary intervention.

###### 

Multivariate logistic regression analysis for clinical predictors of polyvascular disease in patients presenting with acute coronary syndrome.

                      Odds ratio (95% confidence interval)   *P* value
  ------------------- -------------------------------------- -----------
  Age                 1.04 (1.036--1.056)                    0.001
  Male gender         1.13 (0.865--1.466)                    0.34
  Dyslipidemia        1.10 (0.882--1.392)                    0.37
  Diabetes mellitus   2.28 (1.809--2.889)                    0.001
  Hypertension        2.66 (2.028--3.489)                    0.001
  Smoking             1.24 (0.970--1.591)                    0.07
  Obesity             1.003 (0.986--1.020)                   0.62
  Renal failure       2.32 (1.543--3.029)                    0.001

###### 

Multivariate logistic regression analysis for predictors of clinical outcomes in patients with polyvascular disease presenting with acute coronary syndrome.

                       Unadjusted odds ratio (95% CI)   Adjusted odds ratio\* (95% CI)
  -------------------- -------------------------------- ---------------------------------
  Re-ischemia          1.7 (1.37--2.15), *P* = 0.001    1.50 (1.12--2.01), *P* = 0.007
  Heart failure        3.3 (2.67--4.09), *P* = 0.001    2.00 (1.47--2.61), *P* = 0.001
  In-hospital Stroke   4.1 (2.03--8.22), *P* = 0.001    5.40 (2.17--13.29), *P* = 0.001
  Major bleedings      1.61 (0.57--4.52), *P* = 0.36    1.68 (0.54--5.17),  *P* = 0.37
  Hospital death       2.3 (1.66--3.26), *P* = 0.001    1.85 (1.25--2.74), *P* = 0.01
  1-month death        2.5 (1.89--3.29), *P* = 0.001    2.03 (1.46--2.83), *P* = 0.001
  12-month death       2.6 (2.02--3.32), *P* = 0.001    1.83 (1.83--2.45), *P* = 0.003

CI: confidence interval, \*variables adjusted for age, sex, diabetes mellitus, hypertension, dyslipidemia, smoking, renal failure, prior coronary artery disease, and prior coronary revascularization in addition to the type of ACS at presentation.

###### 

Clinical profiles, admission therapy, and outcomes in men and women.

                             ACS alone   Polyvascular disease                               
  -------------------------- ----------- ---------------------- ------- --------- --------- -------
  Age (yrs, mean)            55 ± 12     61 ± 12                0.001   64 ± 12   65 ± 13   0.19
  Diabetes mellitus %        35          51                     0.001   63        74        0.03
  Hypertension %             40.5        64                     0.001   76        81        0.24
  Dyslipidemia %             34          44                     0.001   53        63        0.55
  Smoking %                  65          10                     0.001   57        16        0.001
  Renal failure %            3           5                      0.001   16        13        0.44
  Admission therapy (%)                                                                     
   Aspirin                   98.6        98.5                   0.75    96        97        0.51
   Clopidogrel               79          64                     0.001   82        79        0.51
   Beta blockers             76          71                     0.001   70        63        0.11
   ACE inhibitors            71          72                     0.72    70        65        0.31
   Heparin                   58          59                     0.98    41        37        0.50
   Glycoprotein inhibitors   8.3         5.2                    0.001   9         6         0.23
   Statin                    95          94                     0.01    92        94        0.57
   PCI                       23          19                     0.01    13        10.5      0.55
  Outcomes (%)                                                                              
   Reischemia                14          18                     0.001   21        27        0.17
   Heart failure             10.7        15.5                   0.001   29        34        0.28
   Hospital mortality        3.7         6.3                    0.001   8.6       10.8      0.46
   1-month mortality         6.8         9.7                    0.001   15        20        0.26
   12-month mortality        10.3        15                     0.001   23        29        0.22

###### 

Risk factors and in-hospital mortality in patients with versus without polyvascular disease presenting with acute coronary syndrome in different clinical studies.

                      GRACE (*n* = 32735) \[[@B7]\]   MASCARA (*n* = 6745) \[[@B9]\]   GULFRACE-2  (*n* = 7689)   ALLIANCE (*n* = 8904) \[[@B6]\]                                                                                                          
  ------------------- ------------------------------- -------------------------------- -------------------------- --------------------------------- --------- --------- --------- --------- ------- -------- ------- -------- --------- --------- -------- --------
  Patients %          84                              7                                6                          2                                 83        9         6         2         94      1        4       0.6      87        8         4        1
  Age (mean yrs)      64                              71                               73                         73                                67        70        73        72        56      63       65      66       65        72                 
  Smoking             59                              69                               53                         68                                36/28\*   61/22\*   44/16\*   60/21\*   54      54       39      62       59        63                 
  Diabetes mellitus   22                              38                               34                         42                                28        49        43        52        38      77       61      82       19        34                 
  Hypertension        58                              72                               78                         82                                58        72        76        69        45      72       79      82       48        66                 
  Dyslipidemia        46                              58                               52                         65                                46        57        50        53        36      55       53      67       43        47                 
  Renal failure       N/A                             N/A                              N/A                        N/A                               N/A       N/A       N/A       N/A       3       20       10      30       3         12                 
                                                                                                                                                                                                                                                           
  *Mortality*         **4.5**                         **7.2**                          **8.9**                    **9.2**                           **4.8**   **9.1**   **9.2**   **16**    **4**   **12**   **7**   **15**   **5.7**   **9.8**   **14**   **13**

A: acute coronary syndrome (ACS) alone; B: ACS plus peripheral arterial disease (PAD); C: ACS plus cerebrovascular disease (CVD); D: ACS plus PAD plus CVD; PolyVD: polyvascular disease, all categorical variables represents in percentage (%); DM: diabetes mellitus; N/A: data not available; \*prior/current smoking. Data were collected from \[[@B6], [@B7], [@B9]\].

[^1]: Academic Editors: A. J. Kirtane and L. Kuller
